(b) Single small case series in knee pain A peer-reviewed article (Lee et al., Alternative Therapies in Health & Medicine , ~2021) describes: 12 patients with chronic knee pain Treated with intra-articular BPC-157, often combined with TB-500 7 of 12 reported symptom improvement lasting several months This study has major limitations: No control group No blinding No standardized outcomes (no KOOS, WOMAC, or imaging) Very small sample size Mixed interventions Conclusion: This study cannot demonstrate true benefit
For chronic knee pain with a tendon component, BPC-157 is a reasonable first-line option given its lower cost and sustained daily signaling
found that BPC-157 accelerated the healing of transected rat Achilles tendons when applied topically (dissolved in saline) at a dose of 10 pg.,10 ng, or 10 pg [23]
On the other hand, the adverse events of GLP-1 drugs have been extensively characterized from large randomized trials with placebo controls and, in the United States, from reports derived from 12% of Americans who are currently taking these drugs
